- Previous Close
10.47 - Open
10.50 - Bid 9.98 x 100
- Ask 10.07 x 100
- Day's Range
10.01 - 10.58 - 52 Week Range
8.08 - 17.80 - Volume
201,130 - Avg. Volume
172,496 - Market Cap (intraday)
212.945M - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
-- - EPS (TTM)
-5.45 - Earnings Date Nov 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.00
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
www.enanta.comRecent News: ENTA
View More
Performance Overview: ENTA
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENTA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENTA
View MoreValuation Measures
Market Cap
221.84M
Enterprise Value
42.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.07
Price/Book (mrq)
1.49
Enterprise Value/Revenue
0.59
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-160.27%
Return on Assets (ttm)
-17.18%
Return on Equity (ttm)
-59.64%
Revenue (ttm)
71.96M
Net Income Avi to Common (ttm)
-115.33M
Diluted EPS (ttm)
-5.45
Balance Sheet and Cash Flow
Total Cash (mrq)
230.08M
Total Debt/Equity (mrq)
151.88%
Levered Free Cash Flow (ttm)
-63.27M
Research Analysis: ENTA
View MoreCompany Insights: ENTA
ENTA does not have Company Insights
Research Reports: ENTA
View MoreLowering target price to $10.00
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about ENTA?
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about ENTA?
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $12.00
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target